169 related articles for article (PubMed ID: 21051230)
1. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.
Gupte R; Siddam A; Lu Y; Li W; Fujiwara Y; Panupinthu N; Pham TC; Baker DL; Parrill AL; Gotoh M; Murakami-Murofushi K; Kobayashi S; Mills GB; Tigyi G; Miller DD
Bioorg Med Chem Lett; 2010 Dec; 20(24):7525-8. PubMed ID: 21051230
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of enantiopure 2-carba-cyclic phosphatidic acid and effects of its chirality on biological functions.
Nozaki E; Gotoh M; Hotta H; Hanazawa S; Kobayashi S; Murakami-Murofushi K
Biochim Biophys Acta; 2011 Apr; 1811(4):271-7. PubMed ID: 21277386
[TBL] [Abstract][Full Text] [Related]
3. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Baker DL; Fujiwara Y; Pigg KR; Tsukahara R; Kobayashi S; Murofushi H; Uchiyama A; Murakami-Murofushi K; Koh E; Bandle RW; Byun HS; Bittman R; Fan D; Murph M; Mills GB; Tigyi G
J Biol Chem; 2006 Aug; 281(32):22786-93. PubMed ID: 16782709
[TBL] [Abstract][Full Text] [Related]
4. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.
Altman MK; Gopal V; Jia W; Yu S; Hall H; Mills GB; McGinnis AC; Bartlett MG; Jiang G; Madan D; Prestwich GD; Xu Y; Davies MA; Murph MM
Mol Cancer; 2010 Jun; 9():140. PubMed ID: 20529378
[TBL] [Abstract][Full Text] [Related]
5. Efficient synthesis of 3-O-thia-cPA and preliminary analysis of its biological activity toward autotaxin.
Tanaka R; Kato M; Suzuki T; Nakazaki A; Nozaki E; Gotoh M; Murakami-Murofushi K; Kobayashi S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4180-2. PubMed ID: 21676615
[TBL] [Abstract][Full Text] [Related]
6. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
8. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH
Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid.
Uchiyama A; Mukai M; Fujiwara Y; Kobayashi S; Kawai N; Murofushi H; Inoue M; Enoki S; Tanaka Y; Niki T; Kobayashi T; Tigyi G; Murakami-Murofushi K
Biochim Biophys Acta; 2007 Jan; 1771(1):103-12. PubMed ID: 17123862
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin: a protein with two faces.
Tania M; Khan MA; Zhang H; Li J; Song Y
Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
Durgam GG; Tsukahara R; Makarova N; Walker MD; Fujiwara Y; Pigg KR; Baker DL; Sardar VM; Parrill AL; Tigyi G; Miller DD
Bioorg Med Chem Lett; 2006 Feb; 16(3):633-40. PubMed ID: 16263282
[TBL] [Abstract][Full Text] [Related]
12. Cyclic phosphatidic acid is produced by autotaxin in blood.
Tsuda S; Okudaira S; Moriya-Ito K; Shimamoto C; Tanaka M; Aoki J; Arai H; Murakami-Murofushi K; Kobayashi T
J Biol Chem; 2006 Sep; 281(36):26081-8. PubMed ID: 16837466
[TBL] [Abstract][Full Text] [Related]
13. ATX-LPA receptor axis in inflammation and cancer.
Liu S; Murph M; Panupinthu N; Mills GB
Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract][Full Text] [Related]
16. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
Zhang H; Xu X; Gajewiak J; Tsukahara R; Fujiwara Y; Liu J; Fells JI; Perygin D; Parrill AL; Tigyi G; Prestwich GD
Cancer Res; 2009 Jul; 69(13):5441-9. PubMed ID: 19509223
[TBL] [Abstract][Full Text] [Related]
17. Cyclic phosphatidic acid - a unique bioactive phospholipid.
Fujiwara Y
Biochim Biophys Acta; 2008 Sep; 1781(9):519-24. PubMed ID: 18554524
[TBL] [Abstract][Full Text] [Related]
18. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors.
Tabchy A; Tigyi G; Mills GB
Nat Struct Mol Biol; 2011 Feb; 18(2):117-8. PubMed ID: 21289650
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin and lipid signaling pathways as anticancer targets.
Braddock DT
Curr Opin Investig Drugs; 2010 Jun; 11(6):629-37. PubMed ID: 20496257
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]